Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diatrizoic acid (also known as amidotrizoate) is a high-osmolality iodinated radiocontrast agent. Developed and supplied as an active pharmaceutical ingredient (API) by Laboratorios Juste, it is a small molecule organic iodine compound. Its mechanism of action involves the high atomic weight of iodine atoms, which absorb X-rays, thereby increasing the radiodensity of the tissues or cavities into which it is administered. This allows for the visualization of structures such as blood vessels, the gastrointestinal tract, and the urinary system during diagnostic procedures like angiography, urography, and computed tomography (CT). It has been in clinical use since the 1950s and is available in various salt forms, including meglumine and sodium salts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diatrizoic acid.